Orthofix Medical commenced global commercial launch of the TrueLok Elevate Transverse Bone Transport (TBT) System. TrueLok Elevate represents the first commercially available device in the U.S. with a patented design for use in the TBT procedure to provide a limb preservation treatment option for addressing bony or soft tissue deformities or defects, such as diabetic ulcers.
“The success of the TrueLok Elevate System during the limited market release advances our strategy to become the leading limb reconstruction company in the market, and in particular, expands our presence in the growing diabetic wound market with an innovative solution designed to address a challenging patient population and potentially reduce the burden of complications associated with soft tissue defects including ulcers,” said Patrick Fisher, President of Global Orthopedics for Orthofix. “We are committed to redefining the category of limb reconstruction through further innovation to ensure that our unique portfolio of industry-leading products continues to empower surgeons to excel in limb preservation, extremity deformity correction, limb lengthening and complex fracture management.”
The TrueLok Elevate System represents the latest addition to Orthofix’s flagship product line, the TrueLok family of multiplanar external fixators, including the TrueLok EVO and TL-HEX ring fixation systems. Since receiving FDA clearance and CE registration earlier this year, over 130 TrueLok Elevate procedures have been completed globally under a limited market release.
Orthofix Medical commenced global commercial launch of the TrueLok Elevate Transverse Bone Transport (TBT) System. TrueLok Elevate represents the first commercially available device in the U.S. with a patented design for use in the TBT procedure to provide a limb preservation treatment option for addressing bony or soft tissue deformities or...
Orthofix Medical commenced global commercial launch of the TrueLok Elevate Transverse Bone Transport (TBT) System. TrueLok Elevate represents the first commercially available device in the U.S. with a patented design for use in the TBT procedure to provide a limb preservation treatment option for addressing bony or soft tissue deformities or defects, such as diabetic ulcers.
“The success of the TrueLok Elevate System during the limited market release advances our strategy to become the leading limb reconstruction company in the market, and in particular, expands our presence in the growing diabetic wound market with an innovative solution designed to address a challenging patient population and potentially reduce the burden of complications associated with soft tissue defects including ulcers,” said Patrick Fisher, President of Global Orthopedics for Orthofix. “We are committed to redefining the category of limb reconstruction through further innovation to ensure that our unique portfolio of industry-leading products continues to empower surgeons to excel in limb preservation, extremity deformity correction, limb lengthening and complex fracture management.”
The TrueLok Elevate System represents the latest addition to Orthofix’s flagship product line, the TrueLok family of multiplanar external fixators, including the TrueLok EVO and TL-HEX ring fixation systems. Since receiving FDA clearance and CE registration earlier this year, over 130 TrueLok Elevate procedures have been completed globally under a limited market release.
Copy to clipboard 
